Condition: Heart Transplantation · Sponsor: Rafael Correa-Rocha
The investigators developed a protocol to isolate Treg cells from thymic tissue (thyTreg) discarded in pediatric cardiac surgeries. After completing the pre-clinical studies, the investigators have initiated a phase I/II clinical trial to test the safety and efficacy of the adoptive transfer of autologous thyTreg to prevent rejection in heart transplant children. Condition or disease: Heart Transplantation Intervention/treatment: Regulatory T Cell (Treg) Infusion
This description comes directly from the study's public registry record.
Rafael Correa-Rocha, PhD · 34 915866455 · rafael.correa@iisgm.com
Diana Hernandez Florez, PhD · 34 915290019 · diana.hernandez@iisgm.com
Always discuss trial participation with your own doctor first.
| Hospital General Universitario Gregorio Marañon | Madrid, Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04924491